Home
Search
Search Only:

Search Keyword drug

Total: 48 results found.

Page 1 of 3
... forced into illegality,” he said. Gerhard Mueller-Schwefe, president of the German Society for Pain Therapy, said that the policy change would open up new drug therapy options for patients with chronic ...
... of Tysabri are important to the future of both Elan and Biogen. The drug is considered a highly effective therapy for multiple sclerosis, but its growth has been slower than originally hoped due to concerns ...
... connection with the investigation. Merck, the US drugs group, announced last week that it had also been contacted and was co-operating with investigators.... [Read More] Read more: MSRC Latest MS News ...
An advisory committee of the US Food and Drug Administration (FDA) recommended approval of FTY720 (fingolimod) for the treatment of patients with relapsing multiple sclerosis, the most common form of the ...
A Cannabis-based drug that may relieve symptoms of multiple sclerosis will be denied to Calderdale patients. NHS Calderdale has confirmed the oral spray Sativex will not be routinely funded for the area's ...
A new report, "Extent and causes of international variations in drug usage: a report for the Secretary of State for Health by Professor Sir Mike Richards CBE", names the UK as one of the worst ...
Abstract It has been suggested that natalizumab-associated progressive multifocal leukoencephalopathy may be prevented by structured interruptions of treatment. Evidence supporting such a drug holiday ...
German pharmaceutical and chemicals company Merck KGaA has announced that the U.S. Food and Drug Administration accepted a new drug application for its oral multiple sclerosis treatment Cladribine with ...
Genentech Inc. is licensing a human monoclonal antibody for autoimmune diseases. Financial terms and other aspects of the deal between the South San Francisco-based unit of Swiss drug maker Roche and NovImmune ...
... drug companies, including the maker of Serzone, that a full-disclosure statement would have been about as long as the article itself, so it could appear only on our Web site. The lead author, who was chairman ...
... segments to uncover targeted opportunities for current and emerging drug brands. This series offers a fresh look at a competitive drug market by analyzing physician perception of current and emerging drugs ...
... the company said, which falls within the 1-in-1,000 rate previously seen in clinical trials and implied on the drug's label. Of the total cases, 22 were in the U.S., 32 were in the European Union and ...
New and improved multiple sclerosis (MS) drugs satisfying key unmet needs of oral administration and increased efficacy suggest a paradigm shift in MS therapy; ending the decade long dominance of interferon ...
Abstract FTY720 (Fingolimod) reduces multiple sclerosis disease activity by inducing lymphopenia and inhibiting lymphocyte re-entry from lymph nodes. Peripheral lymphocyte reconstitution following drug ...
Angiotensin II sustains brain inflammation in mice via TGF-β The renin-angiotensin-aldosterone system (RAAS) is a key hormonal system regulating blood pressure. However, expression of RAAS components ...
... and clinicians have a duty to keep unproven therapies from premature use. Similarly, provincial governments should prevent public funds from being diverted to the use of drugs or procedures that lack evidence ...
... option will also be available soon for people living with multiple sclerosis in other countries." Merck Serono will now apply for the listing of Cladribine Tablets within the Russian State Federal drug ...
... of varying efficacy, including antibiotics, steroids, and immuno-modulator drugs. Now, an Italian surgeon, Professor Paolo Zamboni, director of the Centre for Vascular Diseases at the University of Ferrara, ...
... Kingdom for MCT-125. MCT-125 is the company's lead drug candidate for treatment of primary multiple sclerosis-related fatigue (PMSF). In an earlier Phase IIa study, MCT-125 was tested on 138 patients ...
20. Third PML case reported with Rituximab
(News/MS General News)
... according to the FDA and the drug?s manufacturer. The case is the third seen with rituximab in rheumatoid arthritis, according to a ?Dear Healthcare Professional? letter issued by Genentech. The previous ...
«StartPrev123NextEnd»